These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Glinoer D; Etienne-Decerf J; Schrooyen M; Sand G; Hoyoux P; Mahieu P; Winand R Metab Pediatr Syst Ophthalmol (1985); 1988; 11(3):133-40. PubMed ID: 3205168 [TBL] [Abstract][Full Text] [Related]
45. Graves' ophthalmopathy. Correlation of saccadic eye movements with age, presence of optic neuropathy, and extraocular muscle volume. Feldon SE; Levin L; Liu SK Arch Ophthalmol; 1990 Nov; 108(11):1568-71. PubMed ID: 2244842 [TBL] [Abstract][Full Text] [Related]
46. [The influence of treatment of progressive edematous infiltrative ophthalmopathy on intraocular pressure]. Rutecka-Debniak A; Krzystolik Z; Pilarska K; Krzyzanowska-Swiniarska B; Syrenicz A; Jarema A Klin Oczna; 1999; 101(3):195-200. PubMed ID: 10526444 [TBL] [Abstract][Full Text] [Related]
47. The measurement of change in Graves' ophthalmopathy. Gorman CA Thyroid; 1998 Jun; 8(6):539-43. PubMed ID: 9669294 [TBL] [Abstract][Full Text] [Related]
48. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Yokoyama N; Nagataki S; Uetani M; Ashizawa K; Eguchi K Thyroid; 2002 Mar; 12(3):223-7. PubMed ID: 11952043 [TBL] [Abstract][Full Text] [Related]
49. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy. Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139 [TBL] [Abstract][Full Text] [Related]
50. Immunosuppressive treatment of Graves' ophthalmopathy with cyclosporine A. Utech C; Wulle KG; Panitz N; Kiefer H Transplant Proc; 1988 Jun; 20(3 Suppl 4):173-7. PubMed ID: 3381272 [No Abstract] [Full Text] [Related]
51. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908 [TBL] [Abstract][Full Text] [Related]
52. A clinico-investigative profile in Graves' ophthalmopathy. Khurana AK; Sunder S; Ahluwalia BK; Malhotra KC; Gupta S Indian J Ophthalmol; 1992; 40(2):56-8. PubMed ID: 1452284 [TBL] [Abstract][Full Text] [Related]
53. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids. Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760 [TBL] [Abstract][Full Text] [Related]
54. Treatment of severe Graves' ophthalmopathy with cyclosporin A. Utech C; Wulle KG; Bieler EU; Pfannenstiel P; Panitz N; Kiefer H Acta Endocrinol (Copenh); 1985 Dec; 110(4):493-8. PubMed ID: 3911714 [TBL] [Abstract][Full Text] [Related]
55. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy. Tachibana S; Murakami T; Noguchi H; Noguchi Y; Nakashima A; Ohyabu Y; Noguchi S Endocr J; 2010; 57(10):853-61. PubMed ID: 20733265 [TBL] [Abstract][Full Text] [Related]
56. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674 [TBL] [Abstract][Full Text] [Related]
57. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Kung AW; Michon J; Tai KS; Chan FL Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659 [TBL] [Abstract][Full Text] [Related]
58. Can contrast enhanced MRI predict the response of Graves' ophthalmopathy to orbital radiotherapy? Ott M; Breiter N; Albrecht CF; Pradier O; Hess CF; Schmidberger H Br J Radiol; 2002 Jun; 75(894):514-7. PubMed ID: 12124238 [TBL] [Abstract][Full Text] [Related]
59. T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study. Das T; Roos JCP; Patterson AJ; Graves MJ; Murthy R Eye (Lond); 2019 Feb; 33(2):235-243. PubMed ID: 30538310 [TBL] [Abstract][Full Text] [Related]